Poly (Alkyl Cyanoacrylate) Nanoparticles for Use in Treatment of Cancer
US-2021113482-A1 · Apr 22, 2021 · US
Drug delivery system for treatment of cancer
US12433846B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12433846-B2 |
| Application number | US-202117484725-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 24, 2021 |
| Priority date | Mar 27, 2019 |
| Publication date | Oct 7, 2025 |
| Grant date | Oct 7, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein is a hydrophobic anti-cancer drug encapsulated into poly(alkyl cyanoacrylate) nanoparticles and their use in cancer treatments by intracavitary rout of administration such as intraperitoneal administration.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treatment of cancer in a subject, the method comprising intraperitoneally administering to the subject a poly(alkyl cyanoacrylate) nanoparticle, the nanoparticle encapsulating a hydrophobic anti-cancer drug, and wherein the nanoparticle is administered to the subject to treat the cancer in the subject, wherein the poly(alkyl cyanoacrylate) comprises a cyanoacrylate having a 2-ethyl butyl (EBCA) alkyl chain, wherein the nanoparticle does not include a targeting moiety, and wherein the cancer is a primary peritoneal cancer or peritoneal carcinomatosis. 2. The method of claim 1 , wherein the method comprises inhibiting metastasis in the subject. 3. The method of claim 1 , wherein the nanoparticle is produced according to a miniemulsion anionic polymerization process. 4. The method of claim 3 , wherein the nanoparticle has dimensions below 800 nm. 5. The method of claim 3 , wherein the nanoparticle has dimensions from 30 nm to 500 nm. 6. The method of claim 3 , wherein the nanoparticle is PEGylated. 7. The method of claim 1 , wherein the hydrophobic anti-cancer drug comprises 1-90 wt % of the total weight of the nanoparticle. 8. The method of claim 1 , wherein the hydrophobic anti-cancer drug is a taxane. 9. The method of claim 8 , wherein the taxane is cabazitaxel. 10. The method of claim 1 , wherein the cancer is pseudomyxoma peritonei or peritoneal carcinomatosis originating from ovarian cancer, colorectal carcinoma, gastric cancer, renal cancer, rectal carcinoma, pancreatic carcinoma, hepatocellular carcinoma, gallbladder carcinoma, appendiceal malignancies, endometrial carcinoma, cervical cancers, breast cancer, lung cancer, malignant melanoma, adrenocortical carcinoma, or transitional cell carcinoma of the urinary tract. 11. The method of claim 10 , wherein the subject is a human subject.
Assignees
Inventors
Classifications
- A61K31/337Primary
having four-membered rings, e.g. taxol · CPC title
Processes · CPC title
Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title
obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12433846B2 cover?
- Described herein is a hydrophobic anti-cancer drug encapsulated into poly(alkyl cyanoacrylate) nanoparticles and their use in cancer treatments by intracavitary rout of administration such as intraperitoneal administration.
- Who is the assignee on this patent?
- Sintef Tto As, Univ Oslo Hf
- What technology area does this patent fall under?
- Primary CPC classification A61K31/337. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).